At its board meeting on 12 and 13 June, the European Medicines Agency (EMA) announced a delay to the completion of its move to new headquarters in Amsterdam, as well as ongoing staffing issues.
The agency is temporarily working out of the Spark building in Sloterdijk, and it now expects staff to relocate to its new building in the Zuidas area of Amsterdam on 6 January 2020.
The EMA is also experiencing continued personnel difficulties. The staff count of 901 at the end of 2018 has now fallen to 776, and 312 of these employees are telecommuting from the U.K. or working on short-term local contracts. In addition, most of the activities suspended in 2018 -- including the development of guidelines and proactive publication of clinical data -- will continue to remain on hold, the agency said.